Deep Track Capital, LP — 13F Holdings & Portfolio
CIK 1856083 · latest 13F-HR filed 2026-05-15
Deep Track Capital, LP manages $6.12B in 13F-reported U.S. long-equity assets across 63 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are XBI (20.86%), GH (5.04%), IMVT (4.68%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 16 new positions, exited 7, added to 22, and trimmed 19.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$6.12B
Long-equity book
63
Distinct positions
2026-03-31
Filed 2026-05-15
+16 / −7 / ↑22 / ↓19
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- CENTESSA PHARMACEUTICALS PLC$75.4M +150.8%
- ALKERMES PLC$71.0M +126.9%
- OCULAR THERAPEUTIX INC$68.8M +70.2%
- VAXCYTE INC$65.3M +35.4%
- MOONLAKE IMMUNOTHERAPEUTICS$58.7M +96.6%
Top Trims
- CYTOKINETICS INC-$121.5M -57.3%
- STRUCTURE THERAPEUTICS INC-$79.7M -27.9%
- MAZE THERAPEUTICS INC-$72.1M -41.0%
- BIOMARIN PHARMACEUTICAL INC-$71.7M -52.5%
- VIRIDIAN THERAPEUTICS INC-$51.3M -65.3%
New Positions
- ALUMIS INC$149.2M
- NUVALENT INC$141.0M
- GENMAB A/S$98.3M
- DEFINIUM THERAPEUTICS INC$56.7M
- ATAIBECKLEY INC$42.5M
Exited Positions
- DYNAVAX TECHNOLOGIES CORP$241.9M
- MIND MEDICINE MINDMED INC$22.4M
- ATAI BECKLEY NV$19.1M
- XENON PHARMACEUTICALS INC$16.4M
- MONOPAR THERAPEUTICS INC$6.2M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | SPDR SERIES TRUST Put | XBI | 78464A870 | $1.28B | 20.86% | 10,000,000 | SH |
| 2 | GUARDANT HEALTH INC | GH | 40131M109 | $308.4M | 5.04% | 3,338,241 | SH |
| 3 | IMMUNOVANT INC | IMVT | 45258J102 | $286.3M | 4.68% | 11,526,971 | SH |
| 4 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $252.5M | 4.12% | 3,600,000 | SH |
| 5 | VAXCYTE INC | PCVX | 92243G108 | $249.9M | 4.08% | 4,300,000 | SH |
| 6 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $206.3M | 3.37% | 4,279,848 | SH |
| 7 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $185.9M | 3.04% | 1,100,000 | SH |
| 8 | APELLIS PHARMACEUTICALS INC | APLS | 03753U106 | $182.3M | 2.98% | 4,532,374 | SH |
| 9 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $166.7M | 2.72% | 19,686,282 | SH |
| 10 | VERA THERAPEUTICS INC | VERA | 92337R101 | $165.2M | 2.70% | 4,106,067 | SH |
| 11 | ALUMIS INC | ALMS | 022307102 | $149.2M | 2.44% | 6,772,595 | SH |
| 12 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $146.4M | 2.39% | 1,950,000 | SH |
| 13 | NUVALENT INC | NUVL | 670703107 | $141.0M | 2.30% | 1,376,324 | SH |
| 14 | ALKERMES PLC | ALKS | G01767105 | $127.0M | 2.07% | 3,590,323 | SH |
| 15 | CENTESSA PHARMACEUTICALS PLC | CNTA | 152309100 | $125.4M | 2.05% | 3,158,041 | SH |
| 16 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $119.5M | 1.95% | 6,408,863 | SH |
| 17 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $103.8M | 1.70% | 3,477,562 | SH |
| 18 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $99.8M | 1.63% | 2,034,203 | SH |
| 19 | NURIX THERAPEUTICS INC | NRIX | 67080M103 | $98.4M | 1.61% | 6,345,244 | SH |
| 20 | GENMAB A/S | GMAB | 372303206 | $98.3M | 1.61% | 3,663,250 | SH |
| 21 | CYTOKINETICS INC | CYTK | 23282W605 | $90.6M | 1.48% | 1,374,320 | SH |
| 22 | GRAIL INC | GRAL | 384747101 | $89.0M | 1.45% | 1,722,797 | SH |
| 23 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $82.7M | 1.35% | 3,352,804 | SH |
| 24 | MBX BIOSCIENCES INC | MBX | 55287L101 | $82.3M | 1.34% | 2,757,569 | SH |
| 25 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $80.8M | 1.32% | 4,062,500 | SH |
| 26 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $67.3M | 1.10% | 12,161,496 | SH |
| 27 | BIOMARIN PHARMACEUTICAL INC | BMRN | 09061G101 | $65.0M | 1.06% | 1,150,000 | SH |
| 28 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $62.5M | 1.02% | 841,445 | SH |
| 29 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $58.2M | 0.95% | 1,931,884 | SH |
| 30 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $57.5M | 0.94% | 2,750,000 | SH |
| 31 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $56.7M | 0.93% | 3,000,000 | SH |
| 32 | TERNS PHARMACEUTICALS INC | TERN | 880881107 | $56.6M | 0.92% | 1,073,877 | SH |
| 33 | GERON CORP | GERN | 374163103 | $47.3M | 0.77% | 31,720,278 | SH |
| 34 | ANI PHARMACEUTICALS INC | ANIP | 00182C103 | $46.1M | 0.75% | 600,000 | SH |
| 35 | CORMEDIX INC | CRMD | 21900C308 | $42.6M | 0.70% | 6,274,076 | SH |
| 36 | ATAIBECKLEY INC | ATAI | 04650F101 | $42.5M | 0.69% | 12,000,000 | SH |
| 37 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $40.7M | 0.67% | 1,283,979 | SH |
| 38 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $38.5M | 0.63% | 1,000,000 | SH |
| 39 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $36.5M | 0.60% | 2,491,539 | SH |
| 40 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $36.3M | 0.59% | 2,000,000 | SH |
| 41 | SOLENO THERAPEUTICS INC | SLNO | 834203309 | $36.1M | 0.59% | 1,078,710 | SH |
| 42 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $35.0M | 0.57% | 9,345,000 | SH |
| 43 | VERADERMICS INC | MANE | 922967104 | $31.6M | 0.52% | 500,000 | SH |
| 44 | VERASTEM INC | VSTM | 92337C203 | $30.4M | 0.50% | 5,740,850 | SH |
| 45 | ENGENE HOLDINGS INC | ENGNW | 29286M105 | $29.8M | 0.49% | 4,377,572 | SH |
| 46 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $27.3M | 0.45% | 1,393,944 | SH |
| 47 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $26.2M | 0.43% | 6,339,535 | SH |
| 48 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $25.7M | 0.42% | 3,565,062 | SH |
| 49 | ENANTA PHARMACEUTICALS INC | ENTA | 29251M106 | $24.7M | 0.40% | 1,956,867 | SH |
| 50 | APOGEE THERAPEUTICS INC | APGE | 03770N101 | $24.0M | 0.39% | 285,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $6.12B | 63 | 0001856083-26-000003 |
| 2025-12-31 | 2026-02-13 | $5.61B | 55 | 0001856083-26-000001 |
| 2025-09-30 | 2025-11-14 | $3.58B | 56 | 0001856083-25-000006 |